Skip to main content
Premium Trial:

Request an Annual Quote

California Launches Precision Medicine Initiative

NEW YORK(GenomeWeb) – California Gov. Jerry Brown today announced a state initiative to advance precision medicine with $3 million in startup funds. 

The initiative, called the California Initiative to Advance Precision Medicine, will be led by the University of California, San Francisco with participation from the UC system, and will collaborate with public and industry partners. They will start building an infrastructure that brings together resources to advance data, tools, and applications to the practice of precision medicine. UCSF will host the two-year project in conjunction with UC Health. 

The initiative will develop two demonstration projects in disease areas in which the university system and its partners have expertise. The work, Brown's office said, could eventually shed light on why different patients with the same disease may have different responses to the same drugs, as well as why certain diseases, including heart, lung, and kidney disease, and asthma, affect racial and ethnic groups differently. 

Additionally, the project will "inventory" the public and private precision medicine projects in California and bring together experts in medicine, technology, privacy, bioethics, and intellectual property to ensure that data and knowledge is shared safely. 

Brown had already appropriated $3 million in his budget for 2014-2015 for precision medicine projects in the state.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.